Research article · 2014
Research articlePublished 2015
Azilsartan is More Effective as Compared to Olmesartan in Hemodialysis Patients with Uncontrolled Hypertension
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Azilsartan is a new angiotensin receptor blocker with more continuous antihypertensive effects. The objective of this study was to demonstrate the efficacy and safety of azilsartan in hemodialysis patients with uncontrolled hypertension. Methods: Twenty-two hemodialysis patients treated with multiple antihypertensive drugs including olmesartan (20- 40 mg/day) were enrolled in this retrospective observational study. Blood pressure was measured in the morning and evening for a week at baseline and after switching from olmesartan to azilsartan. The patients’ mean blood pressure at baseline was 171/71 mmHg. Olmesartan (20-40 mg/day) was switched to azilsartan with the same dose. An electrocardiogram, an echocardiogram, and measurement of the ankle-brachial index were performed in all patients, and the echocardiogram showed left ventricular hypertrophy in all patients. Home-measured blood pressure, heart rate, and serum potassium were followed for 9 months after switching. Results: Systolic blood pressure was significantly decreased at 1, 3, 6, and 9 months after switching. Diastolic blood pressure was significantly decreased at 3 and 6 months after switching. Switching did not alter the serum potassium level. Conclusions: Switching from olmesartan to azilsartan significantly and safely decreased home-measured blood pressure in hemodialysis patients.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2 Oct 2017
Uncontrolled hypertension is the most common trigger factor of posterior reversible encephalopathy syndrome in patients with chronic kidney disease
Research article · 24 May 2021
Role of ambulatory blood pressure monitoring in management of hypertension in patients with chronic kidney disease on hemodialysis
Conference abstract · 2019
Hypertensive nephropathy as a cause of end stage renal disease: Report from 37 hemodialysis centers in Libya
Conference abstract · 2019
Hemodialysis and hypertension
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Research article · 15 Apr 2026
Anemia Management in Hemodialysis Patients in a Low-resource Setting: Blood Transfusion and Unmet Blood Needs in Burkina Faso
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Akira Ukimura”
- BylineArticles whose byline prints “Hirohisa Matsuda”
- BylineArticles whose byline prints “Yoko Yamauchi”
- BylineArticles whose byline prints “Kazuhisa Yamamoto”
- BylineArticles whose byline prints “Kei Hirai”
- BylineArticles whose byline prints “Nobuyuki Ueno”
- BylineArticles whose byline prints “Hideaki Yasuda”
- BylineArticles whose byline prints “Shuta Ono”

